Viridian Therapeutics (VRDN) Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. CRWV

Go back to Viridian Therapeutics (VRDN) Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Viridian Therapeutic (VRDN) PT Raised to $31 at Goldman Sachs

September 12, 2024 5:07 AM EDT

Goldman Sachs analyst Richard Law raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $31.00 (from $25.00) while maintaining a Buy rating.

The analyst comments "We update our model to reflect increased POS for veligrotug (VRDN-001) following positive topline results from the Ph. 3 THRIVE... More

Viridian Therapeutic (VRDN) PT Raised to $40 at Stifel

September 10, 2024 1:08 PM EDT

Stifel analyst Alex Thompson raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $40.00 (from $33.00) while maintaining a Buy rating.

The analyst comments "We are increasing our PoS for VRDN-001/003 to 80% from 66% following positive topline data from the Ph3 THRIVE study (Our Take... More

Viridian Therapeutic (VRDN) PT Raised to $56 at BTIG

September 10, 2024 11:41 AM EDT

BTIG analyst Julian Harrison raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $56.00 (from $46.00) while maintaining a Buy rating.

The analyst comments "15wk THRIVE (active TED Phase 3) data show veligrotug (fka VRDN-001) with at least comparable proptosis efficacy vs. Tepezza at 24wk, and veligrotug's placebo-corrected rates of diplopia resolution and hearing... More